Highlights from Big Questions during ESMO 2026

ESMO 2026 GU Highlights: VOLGA, DASL-HiCAP, PROTEUS, KEYNOTE-564, LITESPARK-011

ESMO 2026: What Chinese Drug Developers Brought to Madrid

DeLLphi-305 and First-Line SCLC Maintenance | Dr. Jacob Sands at ESMO 2026

Highlights from Who Owns the Message Brunch during ESMO 2026

Tarlatamab After Prior SCLC Treatment | Dr. Charles M. Rudin at ESMO 2026

INTerpath-001 and Personalized Melanoma Therapy | Dr. Matteo Carlino at ESMO 2026

Download ESMO 2026 | Vencer o Câncer

STARBOARD in BRAF-Mutant Melanoma | Prof. Dirk Schadendorf at ESMO 2026

ESMO 2026 | Atualizações e Avanços no Tratamento do Câncer de Pulmão Metastático

DASL-HiCaP Trial Preview | Dr. Tamim Niazi at ESMO 2026

A Vaccine Made for One Person: mRNA vs Melanoma | Peer Reviewed Ep. 4

ESMO Preview: Has Moderna’s Cancer Vaccine Already Passed Goldman’s Test?

TALENT: T-DXd in HER2-Low Early Breast Cancer | Dr. Sara A. Hurvitz at ESMO 2026

32% alive at two years. What does ASTRIDE trial tell us? | Dr. David R. Gandara

Direto de Madrid | O que a ESMO 2026 Mudou no Câncer de Próstata, Rim e Bexiga | Dr. Bruno Benigno

VOLGA and Perioperative Bladder Cancer Therapy | Prof. Thomas B. Powles at ESMO 2026

Zanidatamab in HER2-Positive GEJ Cancer: Updated HORIZON-GEA01 Results from ESMO 2026

INTERPATH Trial Explained 🧬 | Can mRNA Vaccines Prevent Cancer Recurrence? #moderna #keytruda #esmo

ESMO 2026 임박! K-바이오 주목할 관련주는?

ESMO 2026: ¿Quién podrá acceder a la nueva oncología?

Найважливіше з ESMO 2026: новини, що змінюють лікування раку!